Home
 /
Papers
 /
Biochemistry
 /
Atypical GPCR Activation Resolved by Nanobody Engineering
Preprint
Open access
V1
Top 1% · Validated by QED

Atypical GPCR Activation Resolved by Nanobody Engineering

Roman R. Schlimgen, Shawn E. Jenjak, Alexa De La Sancha +9 more
January 2026
 ·
bioRxiv
 ·
DOI 
10.64898/2026.01.10.698836
94
%
Reproducible
QED Impressions
This paper passed independent validation.
QED's automated review checked the evidence supporting each claim, the statistical methods, and whether the results are reproducible from the data provided.

It ranks in the top 1% of preprints assessed in Biochemistry this quarter.
Run full QED analysis
Read paper
Save

Why this is interesting

By demonstrating that ACKR3 activates through ECL2-driven orthosteric pocket expansion—opposite to all canonical GPCRs—this work overturns a core paradigm of receptor pharmacology and opens a generalizable strategy for targeting intractable atypical receptors.

QED claims analysis

Summary

ACKR3 employs an atypical GPCR activation mechanism in which extracellular loop 2 (ECL2) displacement drives orthosteric pocket expansion (~4 Å) that is coupled through transmembrane rearrangements to a unique intracellular aromatic network, enabling ligand-induced activation independent of the conserved W265 toggle switch microswitch and explaining the receptor's broad ligand promiscuity, high basal activity, and resistance to inhibition.

See full analysis
Main Claim 1 –

Antagonist-bound ACKR3 remains active-like and conformationally heterogeneous

Supporting evidence

  • Nanobody–ECL2 interactions tune inverse agonism via M212 rotamers
Main Claim 2 –

ECL2-driven orthosteric pocket expansion controls ACKR3 activation

Supporting evidence

  • Intracellular Y232–Y257–Y315–R142 network stabilizes ACKR3 basal activity
Main Claim 3 –

ACKR3 activation can bypass the conserved W265 toggle switch

Supporting evidence

  • ACKR3 recognizes diverse ligands across multiple molecular families

Abstract

G protein-coupled receptors (GPCRs) are the largest family of clinically targeted proteins, yet most therapeutics target a narrow subset of structurally well-behaved receptors. The atypical chemokine receptor ACKR3 defies canonical models, displaying broad ligand recognition, high basal activity, and resistance to inhibition. Using engineered nanobodies, cryo-EM, NMR, and structure-guided pharmacology, we uncover an unconventional activation mechanism in ACKR3 that challenges established paradigms of GPCR activation. We find that receptor activity is controlled by changes in extracellular pocket volume rather than conformational rearrangements in conserved microswitches, and an expanded aromatic cluster at the intracellular transducer binding pocket stabilizes the active state. These findings redefine how GPCRs can be modulated and open new strategies for targeting pharmacologically intractable receptors.

Related papers

How the QED Score works

QED Score is a validated AI-based quality metric that evaluates life science papers on two dimensions: originality and validity. Each manuscript is anonymized, broken down into its claims and supporting evidence, and examined by specialized AI agents for statistical rigor, consistency across figures, and fit with the existing literature. Scores are percentile ranks, so they're comparable across fields. In blinded tests, expert professors sided with QED Score over journal rank in 75% of decisive cases.
Read the methodology

Free access for academic researchers

Create your free QED account to validate your research, strengthen grant proposals, and uncover scientific insights.
We've sent you an access link.
Please check your inbox.

Didn't get your email? Check your spam folder or reach out to info@qedscience.com

Oops! Something went wrong while submitting the form.
Looking for QED for pharma, biotech or life science organizations?